Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease
Former Novo Nordisk and Pharmanovia executive to lead next growth phase in NAD diagnostics and personalised health innovation
Novo Nordisk continues to position Wegovy as a cornerstone of its obesity treatment portfolio
As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country
Wegovy is now offered in six weekly doses in the EU: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, and the newly approved 7.2 mg dose
The approval introduces a needle-free alternative to injectable GLP-1 therapies
Subscribe To Our Newsletter & Stay Updated
